Literature DB >> 20526793

Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors.

Soley Bayraktar1, Ulas D Bayraktar, Juan C Ramos, Alexandra Stefanovic, Izidore S Lossos.   

Abstract

Primary central nervous system lymphoma (PCNSL) accounts for approximately 4% of all primary brain tumors and has a poor prognosis in both immunocompetent as well as in immunocompromised patients. We conducted a retrospective analysis to examine the clinical characteristics and prognostic factors in HIV-negative and HIV-positive patients with PCNSL and to assess the effect of highly active antiretroviral therapy (HAART) therapy on the outcome of HIV-positive patients. Patients diagnosed with PCNSL between 1999 and 2008 at our institution were divided into two groups based on their HIV status. Their demographic and clinical characteristics were compared using the chi-square test. Kaplan-Meier survival curves were constructed employing the univariate log-rank test. Multivariate analyses of survival were performed by Cox proportional hazards models incorporating the prognostic factors identified in the univariate log rank test. Forty-one HIV-positive patients and 45 HIV-negative patients were identified. HIV-positive patients were younger, more likely to present with seizures and elevated serum LDH levels. There were significant differences in complete remission (CR) rates (P = 0.010) and overall survival (OS) (P = 0.034) in favor of the HIV-negative group. In the HIV-positive group, OS was better in patients with KPS > 70 and patients who received HAART, but remained inferior to that in the HIV-negative patients. HIV-positive patients had a worse prognosis compared to HIV-negative patients despite similar clinical characteristics. Better performance status (KPS > 70) and treatment with HAART conferred better OS in HIV-positive patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20526793      PMCID: PMC9519193          DOI: 10.1007/s11060-010-0252-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  41 in total

1.  Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center.

Authors:  J A Sparano; K Anand; J Desai; R J Mitnick; G E Kalkut; L H Hanau
Journal:  J Acquir Immune Defic Syndr       Date:  1999-08-01       Impact factor: 3.731

Review 2.  Acquired immunodeficiency syndrome-related primary cerebral lymphoma.

Authors:  V S Khoo; K H Liew
Journal:  Clin Oncol (R Coll Radiol)       Date:  1999       Impact factor: 4.126

3.  Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery.

Authors:  C Hoffmann; S Tabrizian; E Wolf; C Eggers; A Stoehr; A Plettenberg; T Buhk; H J Stellbrink; H A Horst; H Jäger; T Rosenkranz
Journal:  AIDS       Date:  2001-11-09       Impact factor: 4.177

Review 4.  Clinical features and diagnosis of primary central nervous system lymphoma.

Authors:  April Fitzsimmons; Kristen Upchurch; Tracy Batchelor
Journal:  Hematol Oncol Clin North Am       Date:  2005-08       Impact factor: 3.722

5.  Reticulum cell sarcoma of the brain. A review of the literature and a study of 19 cases.

Authors:  P Littman; C C Wang
Journal:  Cancer       Date:  1975-05       Impact factor: 6.860

6.  Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome.

Authors:  J Glass; M L Gruber; L Cher; F H Hochberg
Journal:  J Neurosurg       Date:  1994-08       Impact factor: 5.115

7.  Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis.

Authors:  Katherine S Panageas; Elena B Elkin; Lisa M DeAngelis; Leah Ben-Porat; Lauren E Abrey
Journal:  Cancer       Date:  2005-12-01       Impact factor: 6.860

8.  AIDS-related primary brain lymphoma in Michigan, January 1990 to December 2000.

Authors:  Joseph Inungu; Michele Fox Melendez; Jolynn P Montgomery
Journal:  AIDS Patient Care STDS       Date:  2002-03       Impact factor: 5.078

9.  Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.

Authors:  Ryuya Yamanaka; Yoshikatsu Shinbo; Masakazu Sano; Jumpei Homma; Naoto Tsuchiya; Naoki Yajima; Tetsuro Tamura; Hiroaki Hondoh; Hideaki Takahashi; Ken Morii; Kiyoshi Onda; Ryuichi Tanaka
Journal:  Leuk Lymphoma       Date:  2007-06

Review 10.  Central nervous system lymphoma.

Authors:  Andrew Lister; Lauren E Abrey; John T Sandlund
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2002
View more
  25 in total

Review 1.  EBV-associated lymphomas in adults.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Best Pract Res Clin Haematol       Date:  2012-02-05       Impact factor: 3.020

2.  Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas.

Authors:  Ulas Darda Bayraktar; Luis A Diaz; Brittany Ashlock; Ngoc Toomey; Lisa Cabral; Soley Bayraktar; Denise Pereira; Dirk P Dittmer; Juan Carlos Ramos
Journal:  Leuk Lymphoma       Date:  2013-08-28

3.  Outcomes for HIV-positive patients with primary central nervous system lymphoma after high-dose chemotherapy and auto-SCT.

Authors:  A O'Neill; K Mikesch; K Fritsch; B Kasenda; L Banerjee; F Burns; G Zakout; R Johnston; G Illerhaus; K Cwynarski
Journal:  Bone Marrow Transplant       Date:  2015-04-13       Impact factor: 5.483

4.  Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma.

Authors:  F E Valles; C L Perez-Valles; S Regalado; R F Barajas; J L Rubenstein; S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2012-08-30       Impact factor: 3.825

Review 5.  Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes.

Authors:  Kieron Dunleavy; Mark Roschewski; Wyndham H Wilson
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

6.  Prolonged Complete Response in a Pediatric Patient With Primary Peripheral T-Cell Lymphoma of the Central Nervous System.

Authors:  Haneen Shalabi; Anne Angiolillo; Gilbert Vezina; James L Rubenstein; Stefania Pittaluga; Mark Raffeld; Leigh Marcus
Journal:  Pediatr Hematol Oncol       Date:  2015-09-18       Impact factor: 1.969

7.  Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.

Authors:  Vaios Hatzoglou; Jung Hun Oh; Olivia Buck; Xuling Lin; Michelle Lee; Amita Shukla-Dave; Robert J Young; Kyung K Peck; Behroze Vachha; Andrei I Holodny; Christian Grommes
Journal:  J Neurooncol       Date:  2018-08-02       Impact factor: 4.130

Review 8.  LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.

Authors:  Chen Lossos; Soley Bayraktar; Elizabeth Weinzierl; Sheren F Younes; Peter J Hosein; Robert J Tibshirani; Jocelyn Sutton Posthumus; Lisa M DeAngelis; Jeffrey Raizer; David Schiff; Lauren Abrey; Yasodha Natkunam; Izidore S Lossos
Journal:  Br J Haematol       Date:  2014-02-26       Impact factor: 6.998

9.  Anti-LFA-1 antibodies enhance metastasis of ocular lymphoma to the brain and contralateral eye.

Authors:  Jacob Hochman; DeFen Shen; Michael M Gottesman; Chi-Chao Chan
Journal:  Clin Exp Metastasis       Date:  2012-08-05       Impact factor: 5.150

10.  Clinicoradiologic features distinguish tumefactive multiple sclerosis from CNS neoplasms.

Authors:  Xuling Lin; Wai-Yung Yu; Lishya Liauw; Russell Jude Chander; Weiling E Soon; Hwei Yee Lee; Kevin Tan
Journal:  Neurol Clin Pract       Date:  2017-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.